A Study of Acute Kidney Injury in Patients with Snakebite Envenomation

Authors
Dr Prasad Potdukhe¹, Dr Bhushan Naitam², Dr Pranay Gandhi³, Dr Snehal Potdukhe⁴
⁰Associate Professor, Dept of Internal Medicine, GMC, Chandrapur
²Assistant Professor, Pathology, GMCH, Chandrapur
³Assistant Professor, Community medicine, GMCH, Chandrapur
⁴Cosmetologist and Dermatologist, Chandrapur

Corresponding Author
Pranay Gandhi
C/O Dr. Shailendra Gandhi, Near CDCC Bank, Civil Lines, Chandrapur 442401
Email: dr.pranaygandhi@yahoo.co.in, Phone: 9028696449

Abstract
Background and Objectives: Since long Snakebite-related acute kidney injury (AKI) is a common community-acquired AKI in tropical countries leading to death and disability. The aims of this study were to (1) determine the occurrence of snakebite-related AKI, (2) assess factors at presentation that are associated with snakebite-related AKI, and (3) determine the outcomes of patients with snakebite-related AKI.

Methods: We conducted a prospective observational study of patients with snake envenomation at our tertiary hospital during the calender year of 2016. Patient data including baseline characteristics, clinical and laboratory findings, hospital management, and outcomes were recorded in a case report form. A stepwise multivariate logistic regression analysis using a backward selection method determined independent factors significantly associated with AKI.

Results: AKI was observed in 140 patients (54.3%), the majority of whom were AKI stage III (110 patients, 78.6%). AKI occurred at presentation and developed during hospitalization in 88 (62.9%) and 52 patients (37.1%), respectively. Twenty-seven patients died (19.3%), and 69 patients (49.3%) required dialysis. On multivariate logistic regression analysis, (1) snakebites from the Viperidae family (odds ratio [OR]: 9.65, 95% confidence interval [CI]: 2.42–38.44; p = 0.001), (2) WBC >10 × 10⁹ cells/µL (OR: 3.55, 95% CI: 1.35–9.34; p = 0.010), (3) overt disseminated intravascular coagulation (OR: 2.23, 95% CI: 1.02–4.89; p = 0.045), (4) serum creatine kinase >500 IU/L (OR: 4.06, 95% CI: 1.71–9.63; p = 0.001), (5) serum sodium <135 mmol/L (OR: 4.37, 95% CI: 2.04–9.38; p < 0.001), (6) presence of microscopic hematuria (OR: 3.60, 95% CI: 1.45–8.91; p = 0.006)

Conclusions: If we identify factors associated with snakebite-related AKI might help clinicians to be aware of snakebite patients who are at risk of AKI, particularly patients who demonstrate renal tubular dysfunction after Viperidae bites.

Keywords: Snakebite-related acute kidney injury, Prospective study.
Introduction
Since long, Community-acquired acute kidney injury (cAKI) is a major public health problem in tropical countries, particularly in Asia [1,2]. cAKI in tropical countries commonly affects young adults (age range 37–47 years) without pre-existing comorbidities [2]. These patients are at risk of developing chronic kidney disease [3]. cAKI in tropical countries is usually caused by a single etiology including tropical infections, environmental exposure to a toxin, or occupational risk of snakebite envenomation [1,2]. South Asia, Southeast Asia, and sub-Saharan Africa have the highest burden of snakebite envenomation [4]. In Southeast Asia, envenomation by two families of venomous snakes, Elapidae and Viperidae, are associated with significant morbidity and mortality, with fatality rates of 0.4–20.0% [5,6]. Following snakebite envenomation by snakes of the family Viperidae and Crotalidae, patients may develop renal manifestations including proteinuria, hematuria, pigmentation, and AKI [7,8].

Snakebite-related AKI (sAKI) is a type of cAKI reported to affect from 8.0–43.0% of patients with snakebite envenomation [9–15], among whom approximately 15.0–55.0% required renal replacement therapy (RRT) [9–11,13] and the fatality rate was 8.0–39.0% [9–11,13,14]. Previous reports from Brazil have shown greater susceptibility to sAKI with increasing age [16,17]. Reported factors associated with sAKI included age <12 years, time from hospitalization to antivenom treatment >2 h, time from snakebite to receiving antivenom >2 h, longer duration from snakebite to hospital arrival, cellulitis, regional lymphadenopathy, hypotension, higher total bilirubin level, lower hemoglobin level, intravascular hemolysis, incoagulable blood on 20-min whole blood clotting test (20WBCT), prolonged bleeding time, prolonged prothrombin time (PT), hemorrhagic manifestations, serum creatine kinase >2000 IU/L, dark or brown urine color, albuminuria, and longer length of hospitalization [9,10,12,13,15]. Overall, the factors associated with sAKI varied across studies due to differences in the study population, potency and composition of snake venom, which differs across geographic regions of the study sites; accessibility of management facilities; and study design [9,10,12,13,15–17]. Therefore, we conducted this study in our tertiary care hospital among patients during the calendar year 2016 with snakebite envenomation with the aims to assess (1) the occurrence of sAKI from presentation until discharge, (2) clinical and laboratory factors at presentation that independently associated with the development of sAKI, and (3) outcomes of patients with sAKI. This information might help clinicians to identify patients who are at risk for sAKI in order to provide optimal management for decreasing the incidence of cAKI in tropical countries.

Materials and Methods
Study design and population
This prospective observational study was conducted at our tertiary care hospital in central India. The procedure indicated by the Standards for the Reporting of Observation Studies in Epidemiology (STROBE) was followed [20]. The study’s inclusion criteria were patients at least 12 years old and presenting with clinical parameters of snake envenomation. Patients with (1) a history of underlying medical illness including diabetes mellitus, hypertension, neurological diseases, cardiovascular diseases, renal diseases, pulmonary diseases, liver diseases, and hematologic diseases; (2) receiving any antiplatelet or anticoagulant drugs; or (3) currently pregnant were excluded from this study. All snakebite patients in this study were admitted to the hospitals for observation and management. Neurological symptoms and signs were observed every 30 min for 12 h, and then hourly for 12 h in cases of unknown snakebite. Laboratory parameters including complete blood counts, incoagulable blood on 20WBCT, PT, international normalized ratio (INR), activated partial thromboplastin time (aPTT), fibrinogen
level, D-dimer, blood glucose, electrolytes, serum urea, serum creatinine, liver function test, and electrocardiography (ECG) were evaluated at presentation and then as appropriate. Chest X-ray was performed when abnormal lung sounds were detected or upon clinical suspicion of respiratory complications. Urinalysis and spot urine analysis for sodium, potassium, protein, and creatinine were also performed at presentation. Spot urine tests for calcium and phosphate were performed when patients demonstrated hypocalcemia and hypophosphatemia, respectively. Spot urine test for magnesium was performed in patients with hypokalemia.

Treatment outcomes including duration of hospitalization, requirement of RRT, and survival status were summarized on discharge. Patient data including baseline characteristics, location where the snakebite occurred, anatomical site of the bite, type of snake, pre-hospital management, clinical parameters, laboratory findings, hospital management, and outcomes were recorded in a pre-defined case report form.

**Clinical parameters of envenoming from snakes**

The clinical parameters of both local and systemic envenoming were defined according to the WHO 2010 guidelines for the management of snakebites [6]. Local bleeding was defined as prolonged bleeding from fang marks, prolonged bleeding from venipuncture site, and/or bleeding from a recent wound. Spontaneous systemic bleeding manifested as skin bleeding (defined as petechiae, purpura, and/or ecchymosis), mucosal bleeding (defined as gum bleeding, hematemesis, melena, hematochezia, gross hematuria, and/or vaginal bleeding), and/or conjunctival bleeding. Hypotension was defined as systolic blood pressure of <90 mmHg without evidence of tissue hypoperfusion. Capillary leakage was defined as a rise in hematocrit >2.0% above the reference range of adults adjusted for sex and serum albumin <3.0 g/dL. Disseminated intravascular coagulation (DIC) was diagnosed according to the International Society for Thrombosis and Haemostasis (ISTH) scoring system for DIC, with a score ≥5 considered indicative of overt DIC. The score was calculated based on platelet (PLT) count (≥100 × 10^3/μL = 0, <100 × 10^3/μL = 1, <50 × 10^3/μL = 2); D-dimer (<0.5 μg/L = 0, 0.5 to <1.0 μg/L = 1, ≥1.0 to <2.0 μg/L = 2, ≥2 μg/L = 3); PT (<15 s = 0, ≥15 s = 1, >20 s = 2); and fibrinogen level (≥100 mg/dL = 0, <100 mg/dL = 1) [21].

**Management of patients with snake envenoming**

Antivenom treatment was indicated when patients developed local envenoming with the clinical signs of (1) local swelling in more than half of the bitten limb (in the absence of a tourniquet) within 48 h of the bite, (2) rapid extension of swelling over 1 joint within 2 h of a bite on the hands or feet, and/or (3) development of tender lymphadenitis. Antivenom was also indicated for all cases of systemic envenoming, as indicated by the following: (1) hemostatic abnormalities including spontaneous systemic bleeding, incoagulable blood on 20WBCT, and/or thrombocytopenia defined as PLT count <100 × 10^3/μL; (2) neurotoxic signs including ptosis, external ophthalmoplegia, and/or muscle paralysis; (3) cardiovascular abnormalities including hypotension, shock, and/or abnormal ECG; and/or (4) renal abnormalities including reduced urine volume and/or AKI.

Reduced urine volume was classified as oliguria, defined as <400 mL of urine volume in 24 h, or anuria, defined as no urine volume in 24 h. AKI was defined as the increase of serum creatinine ≥0.3 mg/dL within 48 h or increase in serum creatinine ≥1.5 times baseline. AKI staging was performed according to the Kidney Disease: Improving Global Outcomes (KDIGO) clinical practice guidelines. AKI stage I was defined as serum creatinine increased to 1.5 to 1.9 times baseline. AKI stage II was defined as serum creatinine increased to 2.0 to 2.9 times baseline. AKI stage III was defined as serum creatinine increased to 3.0 times baseline or higher, serum creatinine ≥4.0 mg/dL, or receipt of RRT [22].
dosage of acute peritoneal dialysis was assessed using a weekly Kt/V measurement of urea according to the International Society of Peritoneal Dialysis (ISPD) guideline \[23\]. ‘K’ was defined as the volume of dialysate drained multiplied by dialysate/plasma urea concentration, and ‘t’ was defined as the duration of dialysis over 1 week. ‘V’ was defined as the volume of distribution of urea (total body water = 0.5 [female] or 0.6 [male] multiplied by body weight). Snake identification was performed if the snake that definitely bit the patient was brought to the hospital either dead or alive for identification or based on the patients’ description of the snake to the investigators. If the snake could not be identified, the clinical syndrome of envenoming was considered according to the WHO 2010 guidelines for specific antivenom treatment \[6\]. The clinical syndrome of Viperidae envenoming consisted of presentation with (1) local envenoming and (2) clinical bleeding and/or incoagulable blood on 20WBCT. The clinical syndrome of Russell’s viper envenoming consisted of presentation with (1) local envenoming, (2) clinical bleeding and/or incoagulable blood on 20WBCT, and (3) shock defined by a systolic blood pressure of <90 mmHg with evidence of tissue hypoperfusion, i.e., <0.5 mL/kg/h decrease in urine output, cold skin, and/or receipt of inotropic drugs. The clinical syndrome of cobra envenoming consisted of presentation with (1) local envenoming and (2) muscle paralysis.

Sample size calculation
We estimated the required sample size based on a 2013 study from India, which reported a 15% rate of AKI occurrence among patients with snake envenoming \[14\]. Based on this data, a minimum of 196 venomous snakebite patients were needed to achieve this rate with 5% margin of error. We predicted a dropout rate of 20% during this study; therefore, the required sample size was at least 235 patients.

Statistical Analyses
All data were analyzed using SPSS software (version 18.0; SPSS Inc., Chicago, IL). Numerical variables were tested for normality using the Kolmogorov-Smirnov test. Variables with non-normal distribution were summarized as medians and interquartile ranges (IQRs) and compared using Mann-Whitney U tests for two-group comparisons and Kruskal-Wallis tests for greater than two-group comparisons. A significant result on Kruskal-Wallis tests was subjected to further post-hoc pair-wise comparison by using the Mann-Whitney U test with Bonferroni correction to adjust significance values. Categorical variables were expressed as frequencies and percentages and analyzed using chi-squared or Fisher’s exact tests, as appropriate. A univariate logistic regression analysis was used to determine which of the collected baseline characteristics, pre-hospital management, clinical parameters, laboratory findings, and management, were associated with AKI among patients with venomous snakebites. All clinical factors potentially associated with AKI were included in the univariate logistic regression analysis as independent variables, with the occurrence of AKI as the dependent variable. Any variable with a p value ≤ 0.2 was included in a stepwise multivariate logistic regression analysis using a backward selection method for determining significant independent factors. Linear regression analysis was used to predict urine sodium-to-creatinine ratio from serum sodium and urine potassium-to-creatinine ratio from serum potassium. All tests of significance were two-sided, with a p value ≤ 0.05 indicating statistical significance.

Results
Snake identification was possible in 174 patients (67.4%). Identified snakes included Russell’s viper (147 patients, 84.5%), cobra (20 patients, 11.5%), green pit viper (6 patients, 3.4%), and sea snake (1 patient, 0.6%). The median (IQR) age of patients with venomous snakebites was 31.0
Potential factors related to the development of AKI including clinical and laboratory parameters are summarized in Table 2. For any potential factors that had multi-collinearity with each other, only one appropriate factor was chosen.

Comparison of management and outcomes among patients with and without AKI

The potential management characteristics related to the development of AKI are shown in Table 2. Regarding patient outcomes, patients with AKI had a significantly longer duration of hospitalization, greater requirement for RRT, and higher mortality rate (all \( p < 0.001 \)). Of 140 patients with AKI, 27 (19.3%) died, and 113 (80.7%) survived. Clinical parameters and management of deceased and surviving patients with AKI are shown in Table 3. Patients who died were more likely to develop shock, receive inotropic drugs, and demonstrate acute respiratory distress syndrome (ARDS) or respiratory failure (all \( p < 0.001 \)). Of 140 patients with AKI, 69 (49.3%) required RRT. The indications for dialysis included in uremia in 39 patients (56.5%), severe metabolic acidosis in 15 (21.7%), fluid overload in 9 (13.0%), and severe hyperkalemia in 6 (8.7%). The proportions of patients who required RRT were similar between those who died and those who survived. Acute peritoneal dialysis was performed in 62 patients who required RRT (89.8%), and the remaining 7 patients (10.2%) received hemodialysis. The methods of dialysis used in both groups were similar (\( p = 0.118 \)).

Using a univariate logistic regression model, the following clinical parameters were associated with AKI: snakebites of the family Viperidae or presenting the clinical syndrome of Viperidae envenoming, local swelling of grades II to IV, presence of hypotension, WBC count >10 × 10^3 cells/μL, overt DIC, presence of capillary leakage, serum creatinine >500 IU/L, blood sugar ≥150 mg/dL, serum sodium <135 mmol/L, presence of microscopic hematuria, management on a ward, and duration from bite to receipt of antivenom ≥2 h (Table 4).

In a multivariate logistic regression model, the following clinical and laboratory parameters were independently associated with AKI: snakebites of the family Viperidae or presenting the clinical syndrome of Viperidae envenoming (odds ratio [OR]: 9.65; 95% CI: 2.42–38.44; \( p = 0.001 \)), WBC count >10 × 10^3 cells/μL (OR: 3.55, 95% CI: 1.35–9.34; \( p = 0.010 \)), overt DIC (OR: 2.23, 95% CI: 1.02–4.89; \( p = 0.045 \)), serum creatinine >500 IU/L (OR: 4.06, 95% CI: 1.71–9.63; \( p = 0.001 \)), serum sodium <135 mmol/L (OR: 4.37, 95% CI: 2.04–9.38; \( p < 0.001 \)), presence of microscopic hematuria (OR: 3.60, 95% CI: 1.45–8.91; \( p = 0.006 \)), and duration from snakebite to receipt of antivenom ≥2 h (OR: 3.73, 95% CI: 1.48–9.37; \( p = 0.005 \)) (Table 4).

AKI is a common complication after snakebite envenomation from members of the Viperidae family. Thus, factors associated with AKI at presentation and during hospitalization among patients bitten by Viperidae or presenting the clinical syndrome of Viperidae envenoming were identified in this study. Of 214 patients bitten by Viperidae or presenting the clinical syndrome of Viperidae envenoming, 136 (63.6%) developed AKI, including 86 patients (63.2%) with AKI at presentation and 50 (36.8%) who developed AKI during hospitalization. The remaining 78 patients (36.4%) did not develop AKI. Of the 50 patients who developed AKI during hospitalization, 47 (94.0%) developed AKI within 48 h of hospitalization and the remaining 3 patients (6.0%) developed AKI after 48 h of hospitalization.
Clinical parameters, laboratory findings, and management characteristics possibly affecting renal function are shown in Table 5. Patients with the parameters of presence of hypotension ($p < 0.001$), WBC count > $10 \times 10^3$ cells/µL ($p < 0.001$), overt DIC ($p < 0.001$), presence of capillary leakage ($p = 0.001$), serum creatine kinase > 500 IU/L ($p < 0.001$), blood sugar $\geq 150$ mg/dL ($p = 0.015$), serum sodium < 135 mmol/L ($p < 0.001$), presence of microscopic hematuria ($p < 0.001$), and duration from snakebite to receipt of antivenom $\geq 2$ h ($p = 0.021$) were more likely to develop AKI at presentation (Table 5).

These parameters were also associated with AKI at presentation using a univariate logistic regression model (Table 6). In a multivariate logistic regression model, the following clinical and laboratory parameters were independently associated with AKI at presentation: presence of hypotension (odds ratio [OR]: 3.56; 95% CI: 1.05–12.09; $p = 0.042$), serum creatine kinase > 500 IU/L (OR: 6.24, 95% CI: 2.10–18.49; $p = 0.001$), serum sodium < 135 mmol/L (OR: 7.81, 95% CI: 2.87–21.24; $p < 0.001$), presence of microscopic hematuria (OR: 11.45, 95% CI: 3.76–34.82; $p < 0.001$), and duration from snakebite to receipt of antivenom $\geq 2$ h (OR: 7.98, 95% CI: 2.06–30.92; $p = 0.003$) (Table 6).

Clinical parameters, laboratory findings, and management characteristics possibly affecting renal function are shown in Table 7. Patients with the parameters of overt DIC ($p = 0.007$), presence of capillary leakage ($p < 0.001$), serum creatine kinase > 500 IU/L ($p < 0.001$), serum sodium < 135 mmol/L ($p < 0.001$), and who received a total dose of antivenom > 160 mL ($p = 0.016$) were more likely to develop AKI during hospitalization (Table 7).

These parameters were also found to be associated with AKI during hospitalization using a univariate logistic regression model (Table 8). In a multivariate logistic regression model, the following parameters were independently associated with AKI during hospitalization: presence of capillary leakage (odds ratio [OR]: 6.30; 95% CI: 1.13–35.22; $p = 0.036$), serum creatine kinase > 500 IU/L (OR: 4.80, 95% CI: 1.86–12.37; $p = 0.001$), and serum sodium < 135 mmol/L (OR: 4.27, 95% CI: 1.74–10.45; $p = 0.001$) (Table 8).

**Table 1:** Renal manifestations among 258 adults with snakebite envenomation, Yangon, Myanmar, 2015–2016

| Characteristic                        | All | n (%) |
|--------------------------------------|-----|-------|
| **Clinical manifestations**          |     |       |
| Reduced urine volume                 | 258 | 128 (49.6) |
| Renal tenderness                     | 258 | 114 (44.2) |
| Gross hematuria                      | 258 | 46 (17.8) |
| Dark-colored urine                   | 258 | 25 (9.7) |
| **Urinalysis and urine chemistries** |     |       |
| Urine protein-to-creatinine ratio $\geq 1$ | 186 | 112 (60.2) |
| Microscopic hematuria                | 255 | 81 (31.4) |
| Pigmenturia                          | 255 | 38 (14.7) |
| Leukocyturia                         | 255 | 22 (8.5) |
| **Blood chemistry**                  |     |       |
| Acute kidney injury                  | 258 | 140 (54.3) |
| At presentation                      | 140 | 88 (62.9) |
| During hospitalization               | 140 | 52 (37.1) |
| **Serum sodium**                     |     |       |
| Hyponatremia                         | 258 | 115 (44.6) |
| Hypernatremia                        | 258 | 5 (1.9) |
| Serum potassium                      | 258 | 52 (20.2) |
| Hypokalemia                          | 258 | 19 (7.4) |
| Hyperkalemia                         | 258 | 88 (34.4) |
| Hypocalcemia                         | 256 | 6 (2.3) |
| Serum phosphate                      | 256 | 20 (7.8) |
| Hypophosphatemia                     | 256 | 68 (26.6) |
| Serum bicarbonate                    |     |       |
| Metabolic acidosis                   | 258 | 22 (8.5) |
| Metabolic alkalosis                  | 258 | 1 (0.4) |
Table 2: Clinical parameters, laboratory findings, and management characteristics among 258 adults with snakebite envenomation, Yangon, Myanmar, 2015–2016

| Characteristics | All | With acute kidney injury, n (%) | Without acute kidney injury, n (%) | p value |
|-----------------|-----|---------------------------------|-----------------------------------|---------|
| Bites from *Viperidae* or presenting the clinical syndrome of *Viperidae* | | | | |
| Yes | 214 | 136 (62.6) | 78 (36.4) | <0.001 |
| No | 44 | 4 (9.1) | 40 (90.9) | |
| Local swelling | | | | |
| Grades II - IV | 167 | 111 (66.5) | 56 (33.5) | <0.001 |
| Grades 0-1 | 91 | 29 (31.9) | 62 (68.1) | |
| Hypotension | | | | |
| Yes | 69 | 60 (87.0) | 9 (13.0) | <0.001 |
| No | 189 | 80 (42.3) | 109 (57.7) | |
| Laboratory parameters | | | | |
| WBC (cells/μL) | | | | |
| > 10 × 10^3 | 194 | 126 (64.9) | 68 (35.1) | <0.001 |
| ≤ 10 × 10^3 | 64 | 14 (21.9) | 50 (78.1) | |
| Overt DIC | | | | |
| Yes | 147 | 103 (70.1) | 44 (29.9) | <0.001 |
| No | 111 | 37 (33.3) | 74 (66.7) | |
| Capillary leakage | | | | |
| Yes | 35 | 30 (85.7) | 5 (14.3) | <0.001 |
| No | 223 | 110 (49.3) | 113 (50.7) | |
| Creatine kinase (IU/L) | | | | |
| > 500 | 104 | 87 (83.7) | 17 (16.3) | <0.001 |
| ≤ 500 | 152 | 51 (33.6) | 101 (66.4) | |
| Blood sugar (mg/dL) | | | | |
| ≥ 150 | 53 | 37 (69.8) | 16 (30.2) | 0.017 |
| < 150 | 205 | 103 (50.2) | 102 (49.8) | |
| Serum sodium (mmol/L) | | | | |
| < 135 mmol/L | 115 | 91 (79.1) | 24 (20.9) | <0.001 |
| ≥ 135 mmol/L | 143 | 49 (34.3) | 94 (65.7) | |
| Microscopic hematuria | | | | |
| Yes | 81 | 70 (86.4) | 11 (13.6) | <0.001 |
| No | 174 | 67 (38.5) | 107 (61.5) | |
| Management | | | | |
| Site of management | | | | |
| Ward | 211 | 129 (61.1) | 82 (38.9) | <0.001 |
| ICU | 47 | 11 (23.4) | 36 (76.6) | |
| Time from bite to receiving antivenom (hours) | | | | |
| ≥ 2 | 174 | 107 (61.5) | 67 (38.5) | 0.007 |
| < 2 | 76 | 32 (42.1) | 44 (57.9) | |
Table 3: Clinical parameters and management among 140 adults with acute kidney injury (deceased and survivors)

| Characteristics                                      | Deceased          | Survivors         | p value |
|-------------------------------------------------------|-------------------|-------------------|---------|
|                                                       | All n (%)         | All n (%)         |         |
| Time from bite to hospital ≥ 1 h                      | 27 24 (88.9)      | 113 91 (80.5)     | 0.408   |
| Time from bite to receiving antivenom ≥ 2 h           | 27 21 (77.8)      | 112 86 (76.8)     | 1.000   |
| Management in ICU                                     | 27 7 (25.9)       | 113 4 (3.5)       | 0.001   |
| Shock                                                 | 27 20 (74.1)      | 113 34 (30.1)     | <0.001  |
| Received inotropic drugs                              | 27 20 (74.1)      | 113 23 (20.4)     | <0.001  |
| ARDS or respiratory failure                           | 27 13 (48.1)      | 113 9 (8.0)       | <0.001  |
| Required renal replacement therapy                     | 27 13 (48.1)      | 113 56 (49.6)     | 1.000   |
| Received peritoneal dialysis                           | 13 10 (76.9)      | 56 52 (92.9)      | 0.118   |
| Weekly Kt/v, median (IQR)                              | 8 1.9 (1.1–3.0)   | 44 2.7 (2.2–3.9)  | 0.116   |

Table 4: Logistic regression analysis of parameters associated with acute kidney injury, Yangon, Myanmar, 2015–2016

| Characteristic                                           | Univariate analysis | Multivariate analysis |
|----------------------------------------------------------|---------------------|-----------------------|
|                                                         | n  | OR (95% CI) | p value | n  | OR (95% CI) | p value |
| **Clinical parameters**                                  |    |             |         |    |             |         |
| Bites from *Viperidae* or presenting clinical syndrome of *Viperidae* | 258 | 244 |  | 258 | 244 |   |
| Yes                                                     | 17.44 (6.01–50.57) | <0.001 | 9.65 (2.42–38.44) | 0.001 |
| No                                                      | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Local swelling                                          | 258 | 244 |  | 258 | 244 |   |
| Grades II–IV                                            | 4.24 (2.45–7.31)   | <0.001 |  |         |         |
| Grades 0–I                                              | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Hypotension                                             | 258 | 244 |  | 258 | 244 |   |
| Yes                                                     | 9.08 (4.26–19.38)  | <0.001 |  |         |         |
| No                                                      | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| **Laboratory parameters**                               |    |             |         |    |             |         |
| WBC (cells/μL)                                          | 258 | 244 |  | 258 | 244 |   |
| > 10 × 10^3                                             | 6.62 (3.41–12.83)  | <0.001 | 3.55 (1.35–9.34) | 0.010 |
| ≤ 10 × 10^3                                             | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Overt DIC                                               | 258 | 244 |  | 258 | 244 |   |
| Yes                                                     | 4.68 (2.76–7.95)   | <0.001 | 2.23 (1.02–4.89) | 0.045 |
| No                                                      | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Capillary leakage                                       | 258 | 244 |  | 258 | 244 |   |
| Yes                                                     | 6.16 (2.31–16.46)  | <0.001 |  |         |         |
| No                                                      | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Creatine kinase (IU/L)                                  | 256 | 244 |  | 256 | 244 |   |
| > 500                                                   | 10.14 (5.46–18.83) | <0.001 | 4.06 (1.71–9.63) | 0.001 |
| ≤ 500                                                   | 1.00 (Reference)   | 1.00 (Reference)     |         |         |         |
| Characteristics                        | All     | With acute kidney injury, n (%) | Without acute kidney injury, n (%) | p value |
|----------------------------------------|---------|---------------------------------|-----------------------------------|---------|
| Hypotension                            |         |                                 |                                   |         |
| Yes                                    | 46      | 39 (84.8)                       | 7 (15.2)                          | <0.001  |
| No                                     | 118     | 47 (39.8)                       | 71 (60.2)                         |         |
| WBC (cells/μL)                         |         |                                 |                                   |         |
| > 10 × 10^3                            | 122     | 75 (61.5)                       | 47 (38.5)                         | <0.001  |
| ≥ 10 × 10^3                            | 41      | 10 (24.4)                       | 31 (75.6)                         |         |
| Overt DIC                              |         |                                 |                                   |         |
| Yes                                    | 100     | 64 (64.0)                       | 36 (36.0)                         | <0.001  |
| No                                     | 64      | 22 (34.4)                       | 42 (65.6)                         |         |
| Capillary leakage                      |         |                                 |                                   |         |
| Yes                                    | 19      | 17 (89.5)                       | 2 (10.5)                          | 0.001   |
| No                                     | 145     | 69 (47.6)                       | 76 (52.4)                         |         |
| Creatine kinase (IU/L)                 |         |                                 |                                   |         |
| > 500                                  | 69      | 57 (82.6)                       | 12 (17.4)                         | <0.001  |
| ≥ 500                                  | 95      | 29 (30.5)                       | 66 (69.5)                         |         |
| Blood sugar (mg/dL)                    |         |                                 |                                   |         |
| ≥ 150                                  | 38      | 27 (71.1)                       | 11 (28.9)                         | 0.015   |
| < 150                                  | 126     | 59 (46.8)                       | 67 (53.2)                         |         |
| Serum sodium (mmol/L)                  |         |                                 |                                   |         |
| < 135                                  | 77      | 61 (79.2)                       | 16 (20.8)                         | <0.001  |
| ≥ 135                                  | 87      | 25 (28.7)                       | 62 (71.3)                         |         |
| Microscopic hematuria                  |         |                                 |                                   |         |
| Yes                                    | 61      | 51 (83.6)                       | 10 (16.4)                         | <0.001  |
| No                                     | 101     | 33 (32.7)                       | 68 (67.3)                         |         |
| Time from bite to receiving antivenom (hours) | | | | |
| ≥ 2                                    | 112     | 68 (60.7)                       | 44 (39.3)                         | 0.021   |
| < 2                                    | 44      | 17 (38.6)                       | 27 (61.4)                         |         |
Table 6: Univariate and multivariate analysis of clinical and laboratory parameters of adults bitten by Viperidae or presenting the clinical syndrome of Viperidae for identifying acute kidney injury at presentation

| Characteristics                        | All       | With acute kidney injury, n (%) | Without acute kidney injury, n (%) | p value |
|----------------------------------------|-----------|---------------------------------|-----------------------------------|---------|
| Hypotension                            |           |                                 |                                   |         |
| Yes                                    | 46        | 39 (84.8)                       | 7 (15.2)                          | <0.001  |
| No                                     | 118       | 47 (39.8)                       | 71 (60.2)                         |         |
| WBC (cells/μL)                         |           |                                 |                                   |         |
| > 10 x 10^3                            | 122       | 75 (61.5)                       | 47 (38.5)                         | <0.001  |
| ≤ 10 x 10^3                            | 41        | 10 (24.4)                       | 31 (75.6)                         |         |
| Overt DIC                              |           |                                 |                                   |         |
| Yes                                    | 100       | 64 (64.0)                       | 36 (36.0)                         | <0.001  |
| No                                     | 64        | 22 (34.4)                       | 42 (65.6)                         |         |
| Capillary leakage                      |           |                                 |                                   |         |
| Yes                                    | 19        | 17 (89.5)                       | 2 (10.5)                          | 0.001   |
| No                                     | 145       | 69 (47.6)                       | 76 (52.4)                         |         |
| Creatine kinase (IU/L)                 |           |                                 |                                   |         |
| > 500                                  | 69        | 57 (82.6)                       | 12 (17.4)                         | <0.001  |
| ≤ 500                                  | 95        | 29 (30.5)                       | 66 (69.5)                         |         |
| Blood sugar (mg/dL)                    |           |                                 |                                   |         |
| ≥ 150                                  | 38        | 27 (71.1)                       | 11 (28.9)                         | 0.015   |
| < 150                                  | 126       | 59 (46.8)                       | 67 (53.2)                         |         |
| Serum sodium (mmol/L)                  |           |                                 |                                   |         |
| < 135                                  | 77        | 61 (79.2)                       | 16 (20.8)                         | <0.001  |
| ≥ 135                                  | 87        | 25 (28.7)                       | 62 (71.3)                         |         |
| Microscopic hematuria                  |           |                                 |                                   |         |
| Yes                                    | 61        | 51 (83.6)                       | 10 (16.4)                         | <0.001  |
| No                                     | 101       | 33 (32.7)                       | 68 (67.3)                         |         |
| Time from bite to receiving antivenom (hours) | |                                  |                                   |         |
| ≥ 2                                    | 112       | 68 (60.7)                       | 44 (39.3)                         | 0.021   |
| < 2                                    | 44        | 17 (38.6)                       | 27 (61.4)                         |         |
TABLE 7: Clinical parameters, laboratory findings, and management characteristics of 128 adults bitten by *Viperidae* or presenting the clinical syndrome of *Viperidae* (50 patients who developed acute kidney injury during hospitalization and 78 patients without acute kidney injury)

| Characteristics                     | All     | With acute kidney injury, n (%) | Without acute kidney injury, n (%) | p value |
|-------------------------------------|---------|---------------------------------|-----------------------------------|---------|
| **Hypotension**                     |         |                                 |                                   |         |
| Yes                                 | 46      | 39 (84.8)                       | 7 (15.2)                          | <0.001  |
| No                                  | 118     | 47 (39.8)                       | 71 (60.2)                         |         |
| **WBC (cells/μL)**                  |         |                                 |                                   |         |
| > 10 × 10⁴                           | 122     | 75 (61.5)                       | 47 (38.5)                         | <0.001  |
| ≤ 10 × 10⁴                           | 41      | 10 (24.4)                       | 31 (75.6)                         |         |
| **Overt DIC**                       |         |                                 |                                   |         |
| Yes                                 | 100     | 64 (64.0)                       | 36 (36.0)                         | <0.001  |
| No                                  | 64      | 22 (34.4)                       | 42 (65.6)                         |         |
| **Capillary leakage**               |         |                                 |                                   |         |
| Yes                                 | 19      | 17 (89.5)                       | 2 (10.5)                          | 0.001   |
| No                                  | 145     | 69 (47.6)                       | 76 (52.4)                         |         |
| **Creatine kinase (IU/L)**          |         |                                 |                                   |         |
| > 500                                | 69      | 57 (82.6)                       | 12 (17.4)                         | <0.001  |
| ≤ 500                                | 95      | 29 (30.5)                       | 66 (69.5)                         |         |
| **Blood sugar (mg/dL)**             |         |                                 |                                   |         |
| ≥ 150                                | 38      | 27 (71.1)                       | 11 (28.9)                         | 0.015   |
| < 150                                | 126     | 59 (46.8)                       | 67 (53.2)                         |         |
| **Serum sodium (mmol/L)**           |         |                                 |                                   |         |
| < 135                                | 77      | 61 (79.2)                       | 16 (20.8)                         | <0.001  |
| ≥ 135                                | 87      | 25 (28.7)                       | 62 (71.3)                         |         |
| **Microscopic hematuria**           |         |                                 |                                   |         |
| Yes                                 | 61      | 51 (83.6)                       | 10 (16.4)                         | <0.001  |
| No                                  | 101     | 33 (32.7)                       | 68 (67.3)                         |         |
| **Time from bite to receiving antivenom (hours)** | | | | |
| ≥ 2                                 | 112     | 68 (60.7)                       | 44 (39.3)                         | 0.021   |
| < 2                                 | 44      | 17 (38.6)                       | 27 (61.4)                         |         |
DISCUSSION
Snakebite envenomation is one of the common causes of cAKI in tropical countries, particularly in Southeast Asia [1, 2, 4]. The reported incidence of renal involvement with snakebite envenomation ranges from 1.4–28.0% [25, 26]. Renal involvement including proteinuria, hematuria, pigmenturia, and AKI is commonly observed among patients with snakebites from snakes of the family Viperidae [5–8]. Hemotoxic and myotoxic venom, particularly from Russell’s viper and sea snake, are common causes of renal involvement [7, 8]. Similarly, in our study, the majority of patients were bitten by Russell’s viper (84.5%) and clinical renal manifestations were frequent among patients with snakebite envenomation, particularly reduced urine volume (49.6%), renal tenderness (44.2%), and urine protein-to-creatinine ratio ≥1 (60.2%). In Myanmar, proteinuria >1 g/24 h was previously reported in 50.0% of patients with Russell’s viper bites [27] and hematuria in 35.0% of patients with hemotoxic snakebites or the occurrence of glomerulonephritis after snakebite envenomation [7,8]. Previous reports showed that Russell’s viper can cause both intravascular hemolysis and rhabdomyolysis, which is induced by phospholipase A2 in snake venom [7,8]. In our cohort, 140 patients (54.3%) had sAKI according to the criteria of the KDIGO clinical practice guidelines [22]. In previous reports, sAKI was observed in 8.0–43.0% of patients with snakebite envenomation. The higher observed rate
in the present study might be due to differences in criteria for AKI diagnosis, snake species, snake venom potency, and genetic variation of the victims [9–15,19]. In our study, 62.9% of AKI patients had sAKI at presentation, and the rest (37.1%) developed sAKI during hospitalization. Multivariate logistic regression analysis revealed the following parameters to be independently associated with sAKI: bites from snakes of the Viperidae family or presenting the clinical syndrome of Viperidae envenoming, leukocytosis, overt DIC, rhabdomyolysis, hyponatremia, glomerulonephritis, and duration from snakebite to receipt of antivenom ≥2 h. Among patients bitten by Viperidae, the presence of hypotension, rhabdomyolysis, hyponatremia, glomerulonephritis, and duration from snakebite to receipt of antivenom ≥2 h were independently associated with sAKI at presentation. In addition, patients bitten by Viperidae who presented with capillary leakage, rhabdomyolysis, and hyponatremia were at increased risk for the development of sAKI during hospitalization. Previous studies reported similar factors associated with the sAKI, including receipt of antivenom >2 h after snakebite, cellulitis, hypotension, and rhabdomyolysis [9, 10, 13]. A previous case series from Taiwan showed that early specific antivenom treatment within 3 to 6 h after snake envenoming could restore coagulation abnormalities in 1 to 2 days and was effective in reducing the severity of renal damage [28].

Our finding that leukocytosis was associated with sAKI is consistent with a previous experimental study in which leukocytosis was observed after injection of phospholipase A2 and metalloprotease from Russell’s viper venom, which resulted in the elevation of interleukin-6, tumor necrosis factor-α, and prostaglandin E2 leading to increased renal vascular resistance and decreased blood pressure [29].

A previous report from India also showed that the renal pathology of AKI patients with Viperidae bites involved acute tubular necrosis, which might be due to the direct toxicity of the snake venom [30]. However, our patients with sAKI had significantly lower fractional excretion of urea (28.5%) than those without sAKI (42.3%), as well as serum urea-to-creatinine ratio >20 and urine specific gravity of 1.020, indicating renal ischemia that might contribute to the development of sAKI. A previous experimental study revealed massive fibrin deposition in glomerular capillaries, proximal and distal tubular necrosis, and hemolyzed red blood cell casts in the renal tubules of rats subjected to intravascular injection of snake venom, indicating that DIC contributed to renal ischemia in sAKI [31].

Furthermore, snake venom, particularly Viperidae snake venom containing proteolytic enzymes, can destroy the endothelium and basal membrane of capillaries. Thus, capillary permeability increases, albumins escape to the perivascular space, tissue oncotic pressure increases, and plasma oncotic pressure decreases, resulting in a shift of fluid balance from the intravascular to interstitial space, or capillary leakage. The decrease in intravascular volume may be sufficiently severe to compromise circulation, resulting in shock [32]. In cases of severe envenomation, snake venom can induce the release of auto pharmacological vasoactive substances, particularly bradykinin, resulting in vasodilatation and myocardial depression, and consequently reduce myocardial contractility [32]. Therefore, our findings support the pathophysiology of sAKI as multifactorial, including hemodynamic changes, direct toxicity of snake venom, immunologic reaction and pigmenturia [33]. This pathophysiology would explain pathological observation of tubular necrosis, mesangiolysis, cortical necrosis, vasculitis, glomerulonephritis, interstitial nephritis, and renal infarction after snakebite envenomation [33].

In our study, 49.3% of patients with sAKI required RRT, which is within the range of previous reports (15.0–55.0%) [9–11, 13]. The fatality rate was 19.3%, which is also in the reported range (8.0–39.0%) among patients with snakebite envenomation [9–11, 13, 14]. When clinical parameters and management of patients with
sAKI were compared between patients who died and those who survived, patients who died were more likely to develop shock, have pulmonary complications, and receive management in the intensive care unit. However, the proportions of patients who received RRT and peritoneal dialysis as a dialysis method were similar between those who died and survived. The adequacy of dialysis determined by weekly Kt/V was less than 2.1 among AKI patients who died (median: 1.9, IQR: 1.1–3.0), but not among those who survived (median: 2.7, IQR: 2.2–3.9). However, there was no statistically significant difference between the groups, and it is probable that a small number of patients who died (n = 8) were evaluated for weekly Kt/V. According to the ISPD guideline for peritoneal dialysis in AKI, the target weekly Kt/V of 3.5 provides outcomes comparable to that of daily hemodialysis. However, a target weekly Kt/V of 2.1 may be acceptable [23].

In our study, electrolyte abnormalities were common among patients with snakebite envenomation. Patients with snakebite envenomation by a member of the Viperidae family who had hyponatremia at presentation and developed AKI during hospitalization had a significantly higher urine sodium-to-creatinine ratio. Our findings also indicated a significant negative correlation between urine sodium-to-creatinine ratio and serum sodium (r = −0.478), suggesting that hyponatremia among patients with Viperidae snakebites resulted from the renal tubular loss of sodium. Similarly, patients with hypokalemia who developed AKI during hospitalization had a significantly higher urine potassium-to-creatinine ratio. The significant negative correlation of urine potassium-to-creatinine ratio and serum potassium (r = −0.468) suggests that hypokalemia among patients with Viperidae bites resulted from the renal tubular loss of potassium. Moreover, hypomagnesemia was observed in 21.4% of patients with hypokalemia, all of whom had urinary loss of magnesium. Our findings suggested that the renal tubular loss of electrolytes including sodium, potassium and magnesium might be caused by the direct toxicity of snake venom from the Viperidae family. A previous experimental study of Russell’s viper venom demonstrated decreased renal tubular absorption of sodium in proximal and distal renal tubules resulting in increased fractional excretion of sodium due to Na+–K+–ATPase activity inhibition of renal tubules in both the renal cortex and medulla [34]. None of the patients with hypocalcemia had fractional excretion of calcium >20.0% and none of the patients with hypophosphatemia had fractional excretion of phosphate >15.0%, indicating extrarenal causes of hypocalcemia and hypophosphatemia. By contrast, hyperphosphatemia was more commonly observed compared to hypophosphatemia among patients with snakebite envenomation in our study. Thus, hypocalcemia might be caused by the process of intravascular thrombosis following the occurrence of DIC and rhabdomyolysis, and the occurrence of rhabdomyolysis would result in hyperphosphatemia among patients with snakebite envenomation [35, 36]. However, the possibility that hyperphosphatemia might occur secondary to AKI snake envenoming cannot be excluded [37].

**Strengths and limitations**

Our study has some limitations. First, all the data came from an academic tertiary care hospital, which limits the generalizability of the study findings. Second, the snake could be identified in only 67.4% of cases. In case of unidentified snake bites, patient management relied on the clinical syndromes of snakebites defined in the WHO 2010 guidelines. However, our study was conducted as a prospective observational study in order to reduce bias, and the number of study patients achieved the required sample size for adequate statistical power. In addition, this study was the first to demonstrate the occurrence of impaired renal tubular function among patients with normal renal function who received bites from snake of the family Viperidae or having clinical syndrome of Viperidae envenoming.
**Conclusion**

Renal manifestations among patients with snake envenomation included reduce urine volume, renal tenderness, proteinuria, hematuria, electrolytes abnormalities, and AKI, and sAKI was a common and significant complication. The factors associated with sAKI included bites from snakes of the family Viperidae or presenting the clinical syndrome of Viperidae envenoming, duration from bite to receipt of antivenin ≥2 h, leukocytosis, overt DIC, rhabdomyolysis, hyponatremia and presence of microscopic hematuria. Our findings support the hypothesis of multifactorial involvement in the pathogenesis of sAKI. After sustaining Viperidae bites, a significant number of patients with normal renal function developed proximal and distal renal tubular dysfunction. These findings might help clinicians to provide optimal management of patients who are at risk for the development of sAKI in order to reduce the incidence of cAKI in tropical countries in the future.

**References**

1. Jha V, Chugh KS. Community-acquired acute kidney injury in Asia. Semin Nephrol. 2008;28:330–347. doi: 10.1016/j.semnephrol.2008.04.002.
2. Jha V, Parameswaran S. Community-acquired acute kidney injury in tropical countries. Nat Rev Nephrol. 2013;9:278–290. doi: 10.1038/nrneph.2013.36.
3. Chawla LS, Eggers PW, Star RA, Kimmel PL. Acute kidney injury and chronic kidney disease as interconnected syndromes. N Engl J Med. 2014;371:58–66. doi: 10.1056/NEJMra1214243.
4. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, Premaratna R, et al. The global burden of snakebite: a literature analysis and modelling based on regional estimates of envenoming and deaths. Plos Med. 2008;5:e218. doi: 10.1371/journal.pmed.0050218.
5. Chippaux JP. Snake-bites: appraisal of the global situation. Bull World Health Organ. 1998;76:515–524.
6. World Health Organization (WHO) Guidelines for the management of snake-bites in South-East Asia. New Delhi: WHO; 2010.
7. Kanjanabuch T, Sitprija V. Snakebite nephrotoxicity in Asia. Semin Nephrol. 2008;28:363–372. doi: 10.1016/j.semnephrol.2008.04.005.
8. Sitprija V. Snakebite nephropa-thy. Nephrology (Carlton) 2006;11:442–448. doi: 10.1111/j.1440-1715.2006.00599.
9. Pinho FM, Zanetia DM, Burdmann EA. Acute renal failure after Crotalus durissus snakebite: a prospective survey on 100 patients. Kidney Int. 2005;67:659–667. doi: 10.1111/j.1523-1755.2005.67122.
10. Athappan G, Balaji MV, Navaneethan U, Thirumalikolundu subramanian P. Acute renal failure in snake envenomation: a large prospective study. Saudi J Kidney Dis Transpl. 2008;19:404–410.
11. Danis R, Ozmen S, Celen MK, Akin D, Ayaz C, Yazanel O. Snakebite-induced acute kidney injury: data from Southeast Anatolia. Ren Fail. 2008;30:51–55.
12. Paul J, Dasgupta S. Early prediction of acute kidney injury by clinical features of snakebite patients at the time of hospital admission. N Am J Med Sci. 2012;4:216–220.
13. Dharod MV, Patil TB, Deshpande AS, Gulhane RV, Patil MB, Bansod YV. Clinical predictors of acute kidney injury following snake bite envenomation. N Am J Med Sci. 2013;5:594–599.
14. Harshavardhan L, Lokesh AJ, Tejeshwari HL, Halesha BR, Metri SS. A study on the acute kidney injury in snake bite victims in a tertiary care centre. J Clin Diagn Res. 2013;7:853–856.
15. Albuquerque PL, Silva GB, Jr, Jacinto CN, Lima JB, Lima CB, Amaral YS, et al.
Acute kidney injury after snakebite accident treated in a Brazilian tertiary care centre. Nephrology (Carlton) 2014;19:764–770.

16. Silveira PV, Nishioka S, De A. South American rattlesnake bite in a Brazilian teaching hospital. Clinical and epidemiological study of 87 cases, with analysis of factors predictive of renal failure. Trans R Soc Trop Med Hyg. 1992;86:562–564.

17. Nishioka Sde A, Silveira PV. A clinical and epidemiologic study of 292 cases of lance-headed viper bite in a Brazilian teaching hospital. Am J Trop Med Hyg. 1992;47:805–810.

18. Khin M, Nyunt T, Oo NT, Hla Y. Prognostic indicators in patients with snakebite: analysis of 2-year data from township hospital in central Myanmar. WHO South-East Asia J Public Health. 2012;1:144–150.

19. Thein-Than, Tin-Tun, Hla-Pe, Phillips RE, Myint-Lwin, Tin-Nu-Swe, Warrell DA. Development of renal function abnormalities following bites by Russell’s vipers (Daboia russelii siamensis) in Myanmar. Trans R Soc Trop Med Hyg. 1991;85:404–9.

20. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370:1453–1457.

21. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol. 2009;145:24–33.

22. Palevsky PM, Liu KD, Brophy PD, Chawla LS, Parikh CR, Thakar CV, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for acute kidney injury. Am J Kidney Dis. 2013;61:649–672.

23. Cullis B, Abdelraheem M, Abrahams G, Balbi A, Cruz DN, Frishberg Y, et al. Peritoneal dialysis for acute kidney injury. Perit Dial Int. 2014;34:494–517.

24. Leviton AE, Zug GR, Vindum JV, Wogan GOU. Handbook to the dangerously venomous snakes of Myanmar. San Francisco: California Academy of Sciences; 2008.

25. Chugh KS, Pal Y, Chakravarty RN, Datta BN, Mehta R, Sahuja V, et al. Acute renal failure following poisonous snake-bite. Am J Kidney Dis. 1984;4:30–38.

26. Karthik S, Phadke KD. Snakebite-induced acute renal failure. A case report and review of the literature. Pediatr Nephrol. 2004;19:1053–1054.

27. Tin-Nu-Swe, Tin-Tun, Myint-Lwin, Thein-Than, Tun-Pe, Robertson JI, Leckie BJ, Phillips RE, Warrell DA. Renal ischaemia, transient glomerular leak and acute renal tubular damage in patients envenomed by Russell’s vipers (Daboia russelii siamensis) in Myanmar. Trans R Soc Trop Med Hyg. 1993;87:678–81.

28. Hung DZ, Yu YJ, Hsu CL, Lin TJ. Antivenom treatment and renal dysfunction in Russell’s viper snakebite in Taiwan: a case series. Trans R Soc Trop Med Hyg. 2006;100:489–494. doi: 10.1016/j.trstmh.2005.07.020.

29. Mitmoonpitak C, Chulasugandha P, Khow O, Noiprom J, Chaiyabutr N, Sitprij V. Effects of phospholipase A2 and metalloproteinase fractions of Russell’s viper venom on cytokines and renal hemodynamics in dogs. Toxicon. 2013;61:47–53.

30. Vijeth SR, Dutta TK, Shahapurkar J. Correlation of renal status with hematologic profile in viperine bite. Am J Trop Med Hyg. 1997;56:168–170.
31. Burdmann EA, Woronik V, Prado EB, Abdulkader RC, Saldanha LB, Barreto OC, et al. Snakebite-induced acute renal failure: an experimental model. Am J Trop Med Hyg. 1993;48:82–88.

32. Adukauskienė D, Varanauskienė E, Adukauskaitė A. Venomous snakebites. Medicina (Kaunas) 2011;47:461–467.

33. Sitprija V. Animal toxins and the kidney. Nat Clin Pract Nephrol. 2008;4:616–627.

34. Chaiyabutra N, Vasaruchaponga T, Chanhomea L, Rungsipipatb A, Sitprija V. Acute effect of Russell’s viper (Daboia siamensis) venom on renal tubular handling of sodium in isolated rabbit kidney. Asian Biomed. 2014;8:195–202.

35. Chavez LO, Leon M, Einav S, Varon J. Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice. Crit Care. 2016;20:135.

36. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009;361:62–72.

37. Claure-Del Granado R, Bouchard J. Acid-base and electrolyte abnormalities during renal support for acute kidney injury: recognition and management. Blood Purif. 2012;34:186–193.